• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells.

作者信息

Abeykoon Jithma P, Paludo Jonas, Nowakowski Kevin E, Stenson Mary J, King Rebecca L, Wellik Linda E, Wu Xiaosheng, Witzig Thomas E

机构信息

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.

出版信息

Blood Cancer J. 2019 Feb 26;9(3):24. doi: 10.1038/s41408-019-0188-6.

DOI:10.1038/s41408-019-0188-6
PMID:30808874
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6391437/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/887e/6391437/e34e809f5919/41408_2019_188_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/887e/6391437/e34e809f5919/41408_2019_188_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/887e/6391437/e34e809f5919/41408_2019_188_Fig1_HTML.jpg

相似文献

1
The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells.CRM1抑制对人非霍奇金淋巴瘤细胞的影响。
Blood Cancer J. 2019 Feb 26;9(3):24. doi: 10.1038/s41408-019-0188-6.
2
CRM1 as a new therapeutic target for non-Hodgkin lymphoma.CRM1作为非霍奇金淋巴瘤的新治疗靶点。
Leuk Res. 2015 Jan;39(1):38-46. doi: 10.1016/j.leukres.2014.10.003. Epub 2014 Nov 4.
3
CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.CBS9106 是一种新型的可逆口服 CRM1 抑制剂，具有 CRM1 降解活性。
Blood. 2011 Oct 6;118(14):3922-31. doi: 10.1182/blood-2011-01-333138. Epub 2011 Aug 12.
4
Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.核输出选择性抑制剂（SINE）化合物的抗肿瘤活性，在非霍奇金淋巴瘤中通过与mTOR抑制剂及地塞米松联合使用而增强。
Cancer Lett. 2016 Dec 28;383(2):309-317. doi: 10.1016/j.canlet.2016.09.016. Epub 2016 Sep 28.
5
Complex downstream effects of nuclear export inhibition in B-cell lymphomas: a possible role for activation-induced cytidine deaminase (AID).核输出抑制在B细胞淋巴瘤中的复杂下游效应：活化诱导胞嘧啶脱氨酶（AID）的潜在作用。
Haematologica. 2013 Sep;98(9):e111-3. doi: 10.3324/haematol.2013.094540.
6
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.CRM1 和 BRAF 抑制协同作用，诱导 BRAF 突变型黑色素瘤肿瘤消退。
Mol Cancer Ther. 2013 Jul;12(7):1171-9. doi: 10.1158/1535-7163.MCT-12-1171. Epub 2013 Apr 24.
7
Providing activation-induced cytidine deaminase (AID) to nuclear export inhibitors. Response to: "Complex downstream effects of nuclear export inhibition in B-cell lymphomas: a possible role for activation-induced cytidine deaminase".将激活诱导的胞苷脱氨酶（AID）提供给核输出抑制剂。回应：“B细胞淋巴瘤中核输出抑制的复杂下游效应：激活诱导的胞苷脱氨酶的可能作用”
Haematologica. 2013 Sep;98(9):e123. doi: 10.3324/haematol.2013.095299.
8
Prognostic impact and targeting of CRM1 in acute myeloid leukemia.CRM1 在急性髓系白血病中的预后影响和靶向治疗。
Blood. 2013 May 16;121(20):4166-74. doi: 10.1182/blood-2012-08-447581. Epub 2013 Apr 5.
9
Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor.染色体区域维持 1（XPO1/CRM1）作为一种抗癌靶点及其抑制剂的发现。
J Med Chem. 2021 Nov 11;64(21):15534-15548. doi: 10.1021/acs.jmedchem.1c01145. Epub 2021 Oct 20.
10
Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas.用于治疗非霍奇金淋巴瘤的核输出选择性抑制剂。
Haematologica. 2013 Jul;98(7):1098-106. doi: 10.3324/haematol.2012.074781. Epub 2013 Feb 12.

引用本文的文献

1
Exportin 1 (XPO1) Expression and Effectiveness of XPO1 Inhibitor Against Canine Lymphoma Cell Lines.输出蛋白1（XPO1）在犬淋巴瘤细胞系中的表达及XPO1抑制剂的有效性
Vet Sci. 2025 Jul 26;12(8):700. doi: 10.3390/vetsci12080700.
2
A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.一种新型 HSP110 抑制剂，增强了 XPO1 靶向治疗在原发性纵隔 B 细胞淋巴瘤和经典霍奇金淋巴瘤中的作用。
J Exp Clin Cancer Res. 2024 May 22;43(1):148. doi: 10.1186/s13046-024-03068-x.
3
Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors.

本文引用的文献

1
XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.XPO1 抑制剂 Selinexor 通过核内保留 IκB 克服套细胞淋巴瘤中的伊布替尼固有耐药性。
Mol Cancer Ther. 2018 Dec;17(12):2564-2574. doi: 10.1158/1535-7163.MCT-17-0789-ATR.
2
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.塞利尼索联合低剂量硼替佐米和地塞米松治疗复发/难治性多发性骨髓瘤患者。
Blood. 2018 Dec 13;132(24):2546-2554. doi: 10.1182/blood-2018-06-858852. Epub 2018 Oct 23.
3
Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents.
非霍奇金淋巴瘤的核输出及对靶向 XPO1 抑制剂的影响。
Biomolecules. 2023 Jan 5;13(1):111. doi: 10.3390/biom13010111.
4
The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma.染色体区域维持蛋白1（输出蛋白1）梯度表达在大细胞淋巴瘤中的意义
Haematologica. 2021 Aug 1;106(8):2261-2264. doi: 10.3324/haematol.2020.278277.
5
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.水杨酸盐通过诱导 S 期阻滞和损害 DNA 损伤修复来增强 CRM1 抑制剂的抗肿瘤活性。
Blood. 2021 Jan 28;137(4):513-523. doi: 10.1182/blood.2020009013.
6
JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL).JAK3在皮肤T细胞淋巴瘤（CTCL）的恶性T细胞核中表达。
Cancers (Basel). 2021 Jan 14;13(2):280. doi: 10.3390/cancers13020280.
7
Targeting nuclear import and export in hematological malignancies.靶向血液系统恶性肿瘤的核输入和输出。
Leukemia. 2020 Nov;34(11):2875-2886. doi: 10.1038/s41375-020-0958-y. Epub 2020 Jul 5.
8
Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway.CRM1的可逆抑制剂通过阻断NF-κB信号通路使胶质母细胞瘤细胞对辐射敏感。
Cancer Cell Int. 2020 Mar 30;20:97. doi: 10.1186/s12935-020-01186-y. eCollection 2020.
塞利尼索降低DNA损伤修复蛋白的表达，并使癌细胞对DNA损伤剂敏感。
Oncotarget. 2018 Jul 20;9(56):30773-30786. doi: 10.18632/oncotarget.25637.
4
Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin.Selinexor（KPT-330）通过将 IκB 隔离在核内并下调 Survivin 来诱导肿瘤抑制。
Clin Cancer Res. 2017 Aug 1;23(15):4301-4311. doi: 10.1158/1078-0432.CCR-16-2632. Epub 2017 Mar 17.
5
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.XPO1抑制剂与硼替佐米或卡非佐米联合治疗可诱导IκBα的核定位，并克服人多发性骨髓瘤中获得性蛋白酶体抑制剂耐药性。
Oncotarget. 2016 Nov 29;7(48):78896-78909. doi: 10.18632/oncotarget.12969.
6
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.塞利尼索是一种核输出选择性抑制剂（SINE）化合物，通过使核因子κB失活发挥作用，并与蛋白酶体抑制剂联合使用以协同诱导肿瘤细胞死亡。
Oncotarget. 2016 Nov 29;7(48):78883-78895. doi: 10.18632/oncotarget.12428.
7
Selective inhibitors of nuclear export (SINE) in hematological malignancies.血液系统恶性肿瘤中的核输出选择性抑制剂（SINE）
Exp Hematol Oncol. 2015 Mar 1;4:7. doi: 10.1186/s40164-015-0002-5. eCollection 2015.
8
Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.核输出选择性抑制剂（SINE）——一类新型抗癌药物。
J Hematol Oncol. 2014 Oct 15;7:78. doi: 10.1186/s13045-014-0078-0.
9
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.KPT-330 是一种 CRM1（XPO1）介导的核输出抑制剂，在 T 细胞急性淋巴细胞白血病和急性髓系白血病的临床前模型中具有选择性抗白血病活性。
Br J Haematol. 2013 Apr;161(1):117-27. doi: 10.1111/bjh.12231. Epub 2013 Feb 4.
10
Structural basis for leucine-rich nuclear export signal recognition by CRM1.CRM1识别富含亮氨酸的核输出信号的结构基础。
Nature. 2009 Apr 30;458(7242):1136-41. doi: 10.1038/nature07975. Epub 2009 Apr 1.